A comprehensive immunohistochemical analysis of two tissue microarrays (TMA) composed of 107 melanocytic lesions (45 malignant melanomas, 44 naevi of melanoma patients and 18 naevi of healthy controls) detected SLAMF9+ cells in 79.5% of all analyzed tissue samples. This evidence concerns the gene SLAMF9 and melanoma.